Implications of Risk Evaluation and Mitigation Strategy (REMS) programs for managed care pharmacy
| Autor: | Gaurang, Gandhi, Ashley, Chon, Nik, Johnson, Phyllis A, Kidder, Peter, Lee, Kevin, Leung, Ingrid, Ma, Stacey, Ness, Elizabeth, Sampsel, Marissa, Schlaifer, Randall, Seifert, Debora B, Sternaman |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Risk Management
Drug-Related Side Effects and Adverse Reactions business.industry United States Food and Drug Administration Health Policy Managed Care Programs Specialty Pharmaceutical Science Pharmacy medicine.disease United States Risk evaluation Patient safety Nursing Pharmaceutical Services medicine Managed care Humans Medical emergency Patient Safety Health risk business Adverse effect Risk management |
| Zdroj: | Journal of managed care pharmacy : JMCP. 18(3) |
| ISSN: | 1944-706X |
| Popis: | In the last 2 decades, health care management has been challenged by more aggressive therapy, the increased number of specialty medications, and more stringent guidelines to monitor adverse events or health risk. To promote patient safety, various communication requirements are mandated to increase the risk awareness of patients and physicians. These include black-box warnings, "Dear Health Care Provider" letters, U.S. Food and Drug Administration (FDA) Talk Papers, MedGuides, and Risk Minimization Action Plans (RiskMAPs). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|